RWJ 52353

Discontinued Product

3935 has been discontinued.

View all Adrenergic &alpha;<sub>2</sub> Receptors products.
Description: α2D agonist
Chemical Name: 5-(6,7-Dihydrobenzo[b]thien-4-yl-1H-imidazole hydrochloride
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews
Literature (2)

Biological Activity for RWJ 52353

RWJ 52353 is a agonist of the α2D adrenergic receptor (Ki values are 1.5, 254, 443 and 621 nM for α2D, α2A, α1 and α2B adrenergic receptors respectively).

Technical Data for RWJ 52353

M. Wt 202.28
Formula C11H10N2S
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 245744-10-9
PubChem ID 71752148
InChI Key LIHWQUZNTRDJFW-UHFFFAOYSA-N
Smiles C1(SC=C2)=C2C(C3=CN=CN3)=CCC1.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

View Related Products by Target

View Related Products by Product Action

View all Adrenergic α2 Receptor Agonists

Keywords: RWJ 52353, RWJ 52353 supplier, RWJ52353, agonists, alpha2D, a2d, α2d, adrenergic, receptors, adrenoceptors, Adrenergic, Alpha-2, Receptors, 3935, Tocris Bioscience

Citations for RWJ 52353

Citations are publications that use Tocris products.

Currently there are no citations for RWJ 52353.

Reviews for RWJ 52353

There are currently no reviews for this product. Be the first to review RWJ 52353 and earn rewards!

Have you used RWJ 52353?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.